We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sareum Holdings Plc | SAR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.00 | -3.96% | 24.25 | 15:55:35 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 25.25 | 24.25 | 25.25 | 24.25 | 25.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 29/4/2024 17:16 by peaceandlove It's all "ifs, buts and maybes" over at LSE. The share price got to 38p last Wednesday. I repeatly stated it was a pump and dump. The smart investors sold and moved on. You can see the herd has left for pastures new. The not so smart investors (LTH's) are still invested spouting nonsense about £300million here a £billion there LOL particularly SOG who stated earlier today, he felt the share price will reach 45p-50p by the end of the week. A 100% rise from now. Wishful thinking SOG. Perhaps another break for you me thinks.Saftey data for 1801 will give the share price a shot in the name - that's all - maybe reach 50p if lucky before a falling back. People forget 1801 has not be proven to work as of yet. Did you see the link I put up earlier today. TM was talking up licensing deals in June 2020. Sareum Holdings remains a massive gamble. I personally do not feel they'll ever licence their products. All talk and no action. |
Posted at 26/4/2024 09:36 by horridhenry What really sets the mong apart from others stupid enough to respond to him (me), is that he is much more bothered than any of us, and the longer he continues the more stupid he lookshe doesn't differentiate between long term investors confident in their situation and want to talk about it, and others that come and go for a quick profit being confident in your investment is not ramping, and no new investor will put money in based on the posting of long term holders. Peace/Pete/Wolf you are an obsessed Mong. |
Posted at 09/4/2024 22:08 by criticalthinker1 Very on point by the investor on lse who has posted 3 times in 13 years!Twice this evening! They imo are obviously aware of the very poor decisions that have been made when given the recent fundraiser this could have been done when we were at £2.50 ish. This is more than mismanagement by poor decision making acumen given the vitriol we are served about the cvs of appointed individuals to guide the scientific individuals...this is a British company researching drugs for the betterment of society backed by small private investors who have not only been bent over...but the affiliation with CRUK comes into play. Let's not hope this reaches the papers like Sirius Minerals and the marketing they did to get the locals involved which effectively sold out to Anglo American with deep ties to Qatar and the reserves of potash that will be destined to re green elsewhere apart from our green and pleasant land...which is and will be a very similar story that garners attention such as the Post Office/Fujitsu/Horiz Just imagine if a hit job was undertaken on a promising drug development company but it was put on a few years project by a larger pharma with certain assistance to divide the support and hope people forgot...and then it got 'rescued'. EGM NEEDED ASAP. |
Posted at 30/3/2024 22:24 by peaceandlove I honestly think the MHRA didn't authorise Sareum's clinical trial because they felt that the novel formulation isn't a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the trial. In addition, if anyone noticed at the time, Sareum's website stated "the company admits that to go forward through and beyond the Phase 1 trial, it will have to go back to investors to raise more money". This is why I wouldn't trust SOG and Co as far as I could throw them. The happy clappers only state the points that favour Sareum. Not once have they uploaded evidence that Sareum's products are ahead of competitors. SOG and all the happy clappers are small time investors that have gambled their money into a small bio hoping and actually convincing themselves that they're going to be rich. Wolf, they're of their nuts 😆🤣 All of them talk more nonsense than David Icke 😆Seriously, you mark this post when I say I told you so. Unfortunately, more people will invest their hard working money into this company hoping that this is the right one, I'm afraid in my honest opinion this won't come true. However, I expect they'll carry on ramping to the bitter end. Absolute madness!!!!!! Ignore CS, he's on the special brew again. Poor fella. Happy Easter 🐣 |
Posted at 16/3/2024 19:51 by criticalthinker1 OK Wolf. That's a fair shout.But I think it is only fair that investors understand the individuals that Sareum investors are paying for to represent us. I suggest all investors do their own due diligence on the employees of Peel Hunt (and affiliates)and if they feel they have appropriate skill sets. Check it out on LinkedIn Ella Hastings Benjamin Harris Matt Hoole Anup Das Rob Parker Edward Lowe Tom Graham Find Nugent Paul Shackleton Josh Harvey Plenty more I can post but it all stems back to Mr Steel and a certain Mr Parkers affiliations with a previous Peel Hunt employee! Are they worth your SIPPS security? Are they worth our fee? Are they worth our IR dealings? Do they work for the lowly shareholders or someone else. More I can say and blow this right open. Opportunity for the board to step up. |
Posted at 16/3/2024 14:51 by peaceandlove What I see is a man that doesn't won't to admit defeat. Sad, is a firm believer that whatever the dilution and cost to the shareholders, 1801 will come good and Sareum will license etc etc. I just can't see that at this stage.Some of the LSE posters get it, but unfortunately him and over 50% of others are emotionally invested in this company stock. Sar was their answer to giving up work, paying of the mortgage, parties on yachts etc. It's a pipe dream. Very Sad to be honest. I have an element of sympathy for the investors that were encouraged by SOG, Mr Rerate etc. I expect some of them will need psychological support. They need to get their head around why the share price is at 20 odd pence and quick before losing it all. I've seen this many times over the last 20 years. We're always chasing the life changing amount on Aim including me, the problem is only 5% of investors will ever hit the big time of a penny share hitting above a £1. |
Posted at 15/3/2024 09:35 by peaceandlove I know Wolf. Didn't notice until their first reply. I expect it's one of the LSE happy clapper brigade.Nothing has changed. Honestly, I feel the share price will be in single digits very soon. Once that happens the fool will disappear. SOG on LSE trying to justify why Sareum is still a great investment. I actually feel for the guy. Been invested for over 10 years and look where they are. These type of investors crack me up TBH. They seem to think they'll make life changing money from investing in one Aim stock. It just doesn't work like that. Okay 1% may hit the jackpot, but the remaining 99% do not. Unbelievable emotional investors. They'll lose everything. The truth hurts I get it. But once again there is no more money. Without funds the company cannot continue. It'll be very interesting to see if they can raise funds, The share price would definitely fall below 1p. |
Posted at 12/3/2024 18:21 by criticalthinker1 4th Feb 2022 from Sareum BODSSareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Calls extraordinary general meeting for February 28 to approve a 50-into-1 share consolidation. Sareum says its current large number of shares, at 3.40 billion, and low share price create a negative perception among investors. Reducing the number of shares by a factor of 50 will increase the share price and make the stock "more attractive to a broader range of investors", it says. So they decided after apointing Peel Hunt on 29.10.21 that an EGM wad the way forward no doubt on advice from Peel Hunt who we pay! So it is not disproportionate to ask for an EGM from the shareholders is it!? And note if you draw the line on the share price from when Peel Hunt joined it is a direct descent and VERY questionable abilities provided ...so what do they do? We have bolstered our IPR and 737 back 'somewhere'. Still heard no one on lse pick up on my point re where trials take place because we got screwed last time. If they have screwed that then definitely corruption is apparent. We could have raised before around 2.50 But silence on that And plenty more we will look into but don't forget a poster on lse lauded a chap at the last meeting as the introducer. Well what happens to their (at the time) 29000000 shares at exercise price of 5p (at the time) executable by 31.5.26. Like I say more to dovetail re MAERS and NOMAD responsibilities but will get appropriation of who is not doing their job. Which entails fines and possible dismemberment of providing services or acting as a director for x time All best Steadydanny |
Posted at 11/2/2024 20:32 by wolfofwallstreets A poster had just added this on LSE.I'm sure the BOD will lose sleep over it. The BoD must just reF these BBs and laugh and laugh at the idiots on here... Dear Stephen and Tim Having met you both, I believe between you, you BOTH have a responsibility to deliver the above as per the Sareum strategy to investors. I sit here tonight, nearly two months since the AGM, having to read the gloating of a shorter of your last financial "deal" despite you "believing" it to be the best option (with no explanation why?), a share price that has dropped over 60% since that "deal", a bizarre RNS stating SRA737 has been relicensed to an ^unknown", ongoing trials of our lead compound in Australia with no updates of where we are, talk of private investors wanting personnel change and not an iota of direction from either of you. One for the PR Departments, remember we spoke at the AGM - How did JP Morgan Healthcare meet go, any views on Saudi Arabia proposed investment in bio techs? Tim, I was astounded at the AGM when I questioned the lack of confirmation that the data received back from Sierra regarding SRA737 was as stated by them, you "didn't believe necessary to make known", albeit, you waxed lyrical at the '22 AGM how you would go through it in fine detail on it's return! Stephen, you stated at the AGM "we take onboard your comments at the lack of communication". Enough said, I know you read the bb - leave with you to restore some confidence in my belief of the business acumen of Sareum please. GLA So, simple question are the BoD going to respond to shareholders in a diligent manner as per their proclaimed statement. A copy of this posting will be sent to IR@sareum.com during the course of next week, to which, I trust I get a reasoned response. |
Posted at 14/7/2023 00:28 by criticalthinker1 Hi Norma. I need to find the legal bit about selling post a subscription again.. but this is the bit re IHTGCV home page Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more INSIGHTS ALTERNATIVE INVESTMENTS PORTFOLIO DIVERSIFICATION Alyssa Peterson 21 Nov 2022 · 9 min read · Updated on 3 Jan 2023 Share this post Open fast find The Alternative Investment Market: what you need to know as an investor Whilst mainstream stock markets such as the London Stock Exchange are known worldwide, a range of smaller stock markets also exist that enable investors to buy and sell shares of smaller, often earlier-stage companies. The Alternative Investment Market (or AIM) is an example of one such sub-exchange. Launched in 1995 to replace the Unlisted Securities Market, AIM is a smaller branch of the London Stock Exchange. At its launch date, the Alternative Investment Market represented only ten companies, valuing a total of £82 million. Since then, the number of AIM-traded stocks has grown rapidly, helping over 3,700 companies from around the world raise approximately £115 billion, on aggregate. The FTSE Group maintains three real-time indexes for tracking movements on AIM: The FTSE AIM UK 50 Index (firms domestic to the UK only) The FTSE AIM 100 Index (UK and international firms) The FTSE AIM All-Share Index (UK and international firms) AIM-listed companies can often achieve considerably higher levels of investment growth compared to more mature firms quoted on mainstream stock markets. This is primarily due to the early stage at which investors can support businesses with high growth potential, which can be enhanced further due to some AIM-quoted companies being eligible for valuable tax reliefs. Although, it must be noted that accessing companies at an earlier stage is often associated with elevated risk. What type of investor is AIM suitable for? AIM is a relatively high-risk marketplace, meaning that sophisticated investors and high-net-worth individuals (HNWIs) with a large appetite for risk may be attracted by the substantial return potential of investing into AIM-listed companies. But, despite the level of experience with investing in high-risk opportunities, investors should note that due to the relatively small size of AIM-listed companies, as well as a comparative lack of market regulation, this can be a challenging market to navigate. This reiterates the need for investors to undertake thorough due diligence before investing into an AIM opportunity. Examples of companies listed on AIM Attracting companies that are aiming to raise finance, usually between £1 million and £50 million, AIM currently enables firms from 26 countries operating across 37 different sectors to source capital for expansion – providing investors with significant scope for portfolio diversification. Since AIM was launched in 1995, it has facilitated a number of high-profile success stories, including asos.com, the globally renowned online fashion retailer, progressing to list on the London Stock Exchange in February 2022 and now qualifying for the FTSE 250 index. Technology, finance and consumer services are some of the most widely represented sectors within AIM, and a number of well-known companies are currently listed on the exchange, such as: Jet2 plc - a British multinational travel group based in Leeds, specialising in low fare flights from its airline branch, Jet2.com, and package holiday deals from Jet2holidays. YouGov plc - an internet-based market research and data analytics company headquartered in the UK, with operations spanning Europe, North America, the Middle East and Asia-Pacific. Idox plc - a specialist software company built for both the public and private sector, aiming to simplify administration efforts and improve operational efficiency for clients. What is the degree of regulation within the Alternative Investment Market? The process of a company listing on AIM follows a similar path to a traditional IPO but involves comparatively less stringent regulation. For example, there are no set requirements for market capitalisation or the number of shares issued. AIM can be more accessible for smaller companies, due to presenting fewer barriers to entry than the London Stock Exchange. This can subsequently enable risk-seeking investors to access early-stage companies with high growth potential via AIM, helping to accelerate their expansion. As a result, AIM’s reduced regulation can provide the opportunity to benefit early-stage companies, their investors, local communities, and the wider economy. However, reduced levels of regulation can sometimes lead to companies with questionable ethics and business practices floating on AIM. This further reinforces the need for investors to thoroughly understand the companies into which they are investing, ensuring the financial statements are sound and operations align with personal investment goals and values. The role of Nominated Advisers Nominated Advisers (also referred to as Nomads) act as one of the main regulatory forces within AIM. The responsibility of these corporate finance firms (who are approved for the role by the London Stock Exchange) is to guide a company through its AIM admission and through further obligations once AIM trading has begun. Companies that have decided to list on AIM are first required to appoint a Nominated Adviser to help them access the market and to provide a guarantee to shareholders that the operations of the company are acceptable, during both the initial share flotation process and during following periods. However, Nominated Advisers can only help to mitigate the risk of reduced regulation within AIM to some extent, as one concern frequently raised about these firms is that they are responsible for ensuring regulatory compliance, but are also profiting from fees charged to the companies that they advise regarding regulatory compliance. Whilst Nominated Advisers can provide support to AIM-listed companies – and some level of reassurance to investors – additional routes can also be pursued to further ensure that an early-stage company is fulfilling its regulatory requirements and pursuing a realistic path for growth. One of the most popular routes for doing so is investing into early-stage companies via a sophisticated co-investment platform or fund that researches and carefully selects opportunities for investors, based on a defined set of qualifying criteria, for example, often regarding legitimacy and growth potential. What are the benefits of investing in AIM shares? Experienced investors may be interested in AIM-listed companies due to the scope they can provide for tax benefits, as well as the opportunity to invest into companies at an early-stage, potentially offering superior financial returns. 1. Stocks and Shares ISA eligibility Some AIM shares can be included within a Stocks and Shares ISA. Individual Savings Accounts (ISAs) can enable individuals to allocate up to £20,000 annually across the full range of ISA products (including the Stocks and Shares ISA, IFISA, Cash ISA and Lifetime ISA). In turn, when AIM shares are held in a Stocks and Shares ISA (also known as an AIM ISA) investors can realise any dividends and returns free of income tax and capital gains tax (CGT). Whilst ISAs can be beneficial for investors from an income tax and CGT perspective, some investors are not aware of the potential inheritance tax (IHT) implications of these products. Generally, ISAs lose their tax-free status upon their owner’s passing. This means that the beneficiary of the ISA may have to declare it in their tax return, possibly becoming liable to 40% inheritance tax. However, as of August 2013, AIM shares have become eligible to be held within a Stocks and Shares ISA. This means that it is possible to pass on an ISA to any beneficiary completely IHT-free (provided that shares are held for at least two years and are still held upon passing). This is now a possibility because many companies listed on AIM qualify for Business Property Relief (BPR), which enables some businesses and shares to be passed on free of IHT. 2. Potential for EIS eligibility Some companies floating on AIM may qualify to offer shares through the Enterprise Investment Scheme (EIS). A tax-efficient investment scheme designed to incentivise private investment into unlisted early-stage companies, the EIS has attracted over £25 billion of private investment into more than 36,000 small and medium-sized enterprises (SMEs) since being introduced by the UK Government in 1994. Whilst this scheme applies to young, unquoted companies, businesses listed on AIM are classed as being unquoted for EIS purposes. This enables some AIM stocks to qualify for the scheme, providing potential for investors to benefit from a host of tax advantages. The EIS offers five main forms of tax relief for investors, including up to 30% income tax relief, capital gains tax (CGT) exemption, CGT deferral on other assets , 100% inheritance tax relief (provided that shares have been held for a minimum of two years and are still held at the time of the shareholder’s passing), and loss relief, which enables any potential losses to be offset against the investor’s income tax or CGT bill – should the opportunity not exit as planned. Across the scheme, these tax benefits work together to minimise the overall risks and maximise any potential rewards associated with investing in early-stage companies. With some early-stage companies listed on AIM being eligible for the EIS, investors could support the growth of small companies, potentially target high investment returns, benefit from a range of tax reliefs and do so relatively easily, via AIM. 3. Tax relief via VCTs Venture Capital Trusts (VCTs) are investment funds that pool investor capital to then invest into a portfolio of early-stage companies on the investors’ behalf. The value of the portfolio will then dictate investor share value. Specifically, AIM VCTs are funds that focus solely on VCT-qualifying companies listing new shares on AIM. As with all VCTs, investing into an AIM VCT can provide investors with up to 30% income tax relief and tax-free dividends, as long as shares are held for the minimum holding period of five years. The main points of difference between the tax benefits offered by VCTs and the Enterprise Investment Scheme are that VCTs do not provide investors with the opportunity for inheritance tax relief, capital gains tax deferral, and loss relief that investing into an EIS-eligible company can provide. I think you will find Sareum made themselves a favourable option re the above. It is in our legal posted regulatory postings. I will endeavour to find the selling bit with a legal requirement to inform the market. I did post sometime ago. Some disagreed until they read it. Tired now. This is getting tiresome with the 'trading'. Some of the posters on lse I think Afham needs to see they are beyond his fud statements.i believe he is genuinely invested but they are utilising his 'enthusiasm' to trade. Not long until a big bang here imo. Will sort the bit re subscription buyers and need to inform to reclassify. It's not just a share and ipr we are dealing with here. It's the sharks and their mates who are mates with individuals who advise policy and institutional advise ...ahead of public awareness. Not long until they get exposed. Its happening. Just awaiting our time when the wheels within wheels get greased...shame when its about livelihoods |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
